SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE:QGEN). The investigation focuses on Qiagen&#39;s executive officers and

QGEN

Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Investigation into Qiagen Executive Potential Securities Violations Launched

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE:QGEN). The investigation focuses on Qiagen&amp;#39;s executive officers and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel law firm is investigating Qiagen N.V. for potential securities law violations after the company&#039;s disappointing Q1 2026 results prompted a 10% stock decline. The forecast for 2026 sales growth has been lowered, primarily due to reduced demand for QuantiFERON related to immigration testing, raising concerns over executive accountability.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel is investigating claims against Qiagen&#039;s executive officers.</li><li>Qiagen reported a 1% decline in net sales for Q1 2026.</li><li>QuantiFERON product sales fell 5%, impacting entire sales outlook.</li><li>Firmware Cut 2026 sales growth forecast to 1%-2% due to immigration testing drop.</li><li>Qiagen&#039;s stock price dropped 10% following the news.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Johnson Fistel, PLLP (N/A)</strong>: The law firm is investigating Qiagen, raising concerns for investors.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This falls under &#039;Legal&#039; as it involves potential securities law violations impacting investor confidence and QGEN&#039;s legal standing.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Declining sales and lowered forecasts could lead to further stock price depreciation.</li><li>Ongoing investigation may lead to investor litigation costs affecting cash flow.</li><li>Negative market sentiment could persist, influencing investor confidence.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Qiagen&#039;s Q1 2026 sales down 1% on a constant exchange rate.</li><li>Sales for QuantiFERON product fell 5% CER.</li><li>Full-year 2026 sales growth forecast cut to 1%-2%.</li><li>Company cited reduced immigration testing demand as a key factor.</li><li>Qiagen&#039;s stock dropped approximately 10% following the announcement.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting QGEN as legal inquiries may prolong stock weakness in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/QGEN">QGEN</a>). The investigation focuses on Qiagen's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Qiagen securities?</strong><br></br>If you purchased Qiagen securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=7n8Ym52jsqTLiD8oMr41j9FGu8wcIB9_tvPZ65XNTHJiRG5MdeJIobzELKWT6yAvg22KM_kFoXRO_BTQXQ3vhj9PP1JkWXwAUNwPIaHCnBlsvKtD8zb92xVk0LbRY0Yy9caETh98zHqyZr98_os6jRJZOYFnw8rPldjZ9LNFkdE=" rel="nofollow" target="_blank">Click here to join the investigation</a>.</p>  <p>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate ("CER") basis, and that sales of its QuantiFERON product declined approximately 5% CER.</p>  <p>In addition, Qiagen lowered its full-year 2026 outlook, reducing its expected sales growth to approximately 1% to 2% CER. The Company attributed the weaker performance, in part, to a "significant decline in immigration testing demand," which impacted its QuantiFERON franchise.</p>  <p>Following this disclosure, Qiagen's stock price declined approximately 10%, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Qiagen complied with the federal securities laws. If you suffered losses from your investment in Qiagen stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=xxZqihVEJHGyrWIW4RC9_AjZOleqEDVvonJ0Uzquwp_JqFpAOtq8FVDl_6wayDJnikHvY4O2YahTsDZF6HyzvzbxVKp1owFTd2WSYIPHFvk=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.</p>  <p>Past results do not guarantee future outcomes.</p>  <p>Services may be performed by attorneys in any of our offices.</p>  <p>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwOTEyOSM3NTcxNzE0IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OTE5YTg3MzUtNTZmNS00ZWU1LTgxMDktODliNWVjNmQxMGUzLTExOTMzNTgtMjAyNi0wNC0yOS1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel law firm is investigating Qiagen N.V. for potential securities law violations after the company's disappointing Q1 2026 results prompted a 10% stock decline. The forecast for 2026 sales growth has been lowered, primarily due to reduced demand for QuantiFERON related to immigration testing, raising concerns over executive accountability.

Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News